Spain
Reimbursed Care Access
Spain permits licensed pharmaceutical use of esketamine (Spravato) under AEMPS regulation but routine public reimbursement is limited; ketamine is used off‑label in private clinics (self‑pay) for mood disorders. Most classic psychedelics (psilocybin, MDMA, DMT, 5‑MeO‑DMT, mescaline, 2C‑X, ibogaine) remain controlled with no authorised outpatient medical programmes—plant preparations such as ayahuasca occupy a judicial/administrative grey zone that has allowed private ceremonial use in some regions under narrow circumstances.
📜History of research in Spain
Spain's engagement with psychedelic substances follows the broad arc of international psychopharmacology rather than a wholly distinct national trajectory. The chemical synthesis of lysergic acid diethylamide (LSD) by Albert Hofmann in 1938 and the subsequent marketing of LSD as Delysid by Sandoz in the 1950s made powerful serotonergic compounds available to psychiatrists and researchers across Europe. Sandoz's international distribution of Delysid to medical and research centres in the 1950s and 1960s facilitated early experimental and clinical work in many countries; Spain, like other European states, was exposed to these developments within psychiatric and neuroscientific communities.
From the late 1960s and into the 1970s international scheduling and national drug-control measures curtailed much formal research with classical psychedelics. Spain enacted strict controls on the manufacture, distribution and possession of a range of psychoactive substances during the late 20th century, and for several decades clinical and academic work on LSD, psilocybin and MDMA was very limited relative to the immediate post-war years.
Beginning in the 1990s and accelerating through the 2000s and 2010s, Spain experienced a renaissance in scientific and clinical interest in psychedelic compounds. Spanish neuroscientists, psychiatrists and psychopharmacologists increasingly engaged in neuroimaging studies, observational research on traditional and entheogenic preparations (for example ayahuasca), and clinical research on rapidly acting antidepressants such as ketamine. Major academic centres and metropolitan hospitals in Madrid and Barcelona expanded psychopharmacology and neuropsychiatriy programmes that began to include psychedelic-related projects and international collaborations.
In the most recent decade the landscape has become plural and dynamic: academic groups, hospital departments, non-governmental associations and private clinics contribute to a mixed ecology of basic neuroscience, small-scale clinical trials, observational studies and off-label therapeutic practice (notably ketamine). Spanish researchers now participate in international consortia and publish in peer-reviewed neuropsychopharmacology and psychiatry journals, while national regulation continues to treat classical psychedelics as controlled substances and the medical use of authorised compounds is governed by existing pharmaceutical and health-care frameworks.
🔬Research Focus
Current Spanish research strengths centre on translational neuroscience and clinical psychiatry. Neuroimaging and psychopharmacology groups at major universities and hospitals have emphasised mechanistic studies—using functional MRI and EEG—to understand how serotonergic psychedelics and dissociatives alter brain network dynamics. Clinically, most activity is focused on treatment-resistant depression and acute interventions (including ketamine), substance-use disorders and preliminary work on end-of-life distress and obsessive-compulsive symptoms. Observational and ethnographic research into traditional plant-based medicines (for example ayahuasca) has also been an empirical focus for some Spanish teams.
In terms of compounds, ketamine is the most practically integrated into Spanish clinical practice because it is an authorised medicinal anaesthetic with recognised antidepressant properties when used off-label; as a result private and some public clinics offer ketamine-assisted interventions. Research into psilocybin and MDMA is growing but remains concentrated in early-phase clinical trials, observational studies and experimental neuroimaging rather than large Phase III trials. Spanish investigators also contribute to collaborative European research networks that pool data and expertise across centres, supporting methodological development in psychotherapy integration, safety monitoring and neurobiological biomarkers.
🏆Key Milestones
🚀Future Outlook
Over the next 12–24 months Spain is likely to see incremental rather than revolutionary change. Expect an increase in early-phase clinical trials of psilocybin and MDMA within academic centres, greater participation in multi-centre European studies, and expanded neuroimaging work to identify biomarkers of treatment response. The growth of regulated, clinic-based ketamine services will probably continue, prompting demand for formalised clinical training, safety guidelines and outcome monitoring.
Regulatory developments are apt to remain cautious: full marketing approvals for psilocybin or MDMA at a national level are unlikely within two years, but there may be more structured pathways for compassionate use, clinical trials and research licenses. Public and professional debate, together with accumulating international efficacy and safety data, should drive the creation of national clinical protocols, practitioner training programmes and tighter oversight of private practice during this period.